Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Structure Therapeutics Inc. is a Cayman Islands ... Keeping to its late-stage assets, subcutaneous triple (GIP/GLP-1/glucagon RA) agonist retatrutide demonstrated an eye-popping 24% weight ...

Structure Therapeutics’ GSBR-1290 cut weight ... In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic ...

To determine which GLP-1 RA may work best for you, your doctor will consider your blood sugar patterns and health history. Short-acting GLP-1 RAs stay in your body for less than a day. They help ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

G lucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...

GLP-1 RAs were associated with significant reductions in body weight, BMI, and waist circumference among pediatric patients with obesity.

treatment with a glucagon-like peptide 1 receptor agonist (GLP-1 RA) may protect against progression to cirrhosis and mortality; however, the protective benefits do not extend to patients who ...

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...